OBJECTIVE: NIPT side steps many of the issues associated with invasive fetal testing, and has become a popular screening tool in assessing chromosome abnormalities when fetal anomalies are identified. Our clinical experience suggested NIPT has low yield in fetuses with heart defects. This study describes the utility of NIPT in specific classes of congenital heart disease. STUDY DESIGN: Retrospective chart analysis identified pregnancies with isolated (I) or non-isolated (NI) fetal CHD. Inclusion criteria: confirmed cardiac diagnosis, prenatal NIPT results known, abnormal postnatal chromosome results. CHDs were classified based on their embryological development: 1) hypoplastic left heart (HLH); 2) transposition of great arteries (TGA); 3) truncus arteriosus (TA); 4) conotruncal defects (CT); 5) atrioventricular septal defect (AVSD); 6) muscular septal defects (mVSD); 7) right aortic arch (RAA); 8) coarctation of aorta (CoA)/interrupted aortic arch (IAA); and, 9) right sided defects. Utility of NIPT was defined as the chance NIPT could provide a causative diagnosis for the CHD ( T21, T18, T13, 45,X, triploidy, del22q11.2) to the patient to supplant invasive testing in confirmed (I) and (NI) CHD groups RESULTS: Eighty two babies with abnormal chromosomes were studied, 57 with isolated defects and 25 with both cardiac and extracardiac abnormality. Table 1 shows the percentage of cases predicted accurately by NIPT, ordered by CHD class. The highest utility of NIPT in (I) and (NI) cases was in cases with TA or AVSD, 100% and 94.4%, respectively. NIPT gave no valuable information in isolated HPLH, TGA, or RAA. Overall yield of NIPT was 64% for isolated CHD, 70.7% for non-isolated cases. Genetic conditions not identified by NIPT in NI CHD cases include microarray abnormalities and single gene conditions (Noonan syndrome). Two cases of aortic coarctation were diagnosed with mosaic Turner syndrome; the technology of NIPT may be limited in mosaic cases. CONCLUSION: NIPT has satisfactory (although not complete) utility in AVSD and CT abnormalities more often associated with standard aneuploidies. A low-risk result from NIPT does not eliminate microarray abnormality for all other types of CHD and is not reliable enough to substitute for invasive fetal testing. Invasive procedures have modest associated risks, but the additional information they provide may be key for families and healthcare providers. The CHD category is an important factor to consider if NIPT is offered as an option.
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890 Clinical outcomes of genome-wide cfDNA for cases screening positive for trisomy 9 Erica L. Soster, Theresa Boomer Integrated Genetics, Westborough, MA OBJECTIVE: Cell-free DNA (cfDNA) testing has been integrated into routine prenatal care. Expansion of cfDNA technology includes select microdeletions, large copy number variants, and esoteric aneuploidies. Initial data regarding outcomes from a commercial genome-wide cfDNA test has been described. 1, 2, 3 The objective is to describe the clinical outcomes observed for cases positive for trisomy 9 (T9). STUDY DESIGN: A retrospective analysis was performed on over 40,000 maternal blood samples submitted for genome-wide cfDNA analysis. Samples were subjected to DNA extraction, library preparation, and genome-wide massively parallel sequencing.
4 Sequencing data were analyzed using a novel algorithm to detect trisomies and subchromosomal, genome-wide copy number variants 7Mb and larger.
1 The cases that screened positive for T9 were reviewed. Clinical outcomes were requested from ordering providers as part of routine follow-up of positive cases. RESULTS: Ten cases screened positive for T9. Based on diagnostic testing, 2 cases were confirmed mosaic fetal events while 2 cases were events that appeared confined to the placenta. Three additional cases ended in miscarriage/fetal demise without informative confirmatory testing. One case, which had mosaic sequencing data, had normal diagnostic testing and was classified as discordant. Another case with mosaic sequencing data is ongoing with normal amniocentesis, but without available clinical outcome. The final case is lost to follow-up, but had an abnormal serum biochemical screen. Of cases with available outcome, 5/7 cases had an adverse outcome, defined as growth restriction, preterm labor, miscarriage/fetal demise, or structural ultrasound anomalies based on provider feedback. CONCLUSION: Positive results for T9 on cfDNA may carry residual risk for fetal aneuploidy, confined placental mosaicism, and adverse outcome. Adverse outcomes have been reported in other cohorts of T9 cfDNA cases. 5, 6 Cases of both full and mosaic T9 have been reported in livebirths, often with significant structural anomalies. 7 Discrepancies in cytogenetic results between different tissues, such as amniotic fluid and postnatal blood, may complicate prenatal and postnatal diagnosis of this condition.
8 Consideration of the potential outcomes will be an important counseling tool for providers and patients alike.
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